PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Molecules
827812695	rs1105879	PMID:21806385	UGT1A6	Genotype AC is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype AA.	yes	< 1.0E-4	162		East Asian	Dosage,Metabolism/PK	false	Reported as UGT1A6 variant 552A>C.	valproic acid
981859205	rs2298771	PMCID:PMC3125053	SCN1A	Allele C is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin and valproic acid in people with Epilepsy as compared to allele T.	no	= 0.91	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1183629452	rs3219151	PMID:24061200	GABRA6	Allele C is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele T.	no	= 0.587	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1448107604	rs1105879	PMID:15761113	UGT1A6	Allele C is associated with increased glucuronidation of valproic acid in HEK 293 cells..	yes					Metabolism/PK	false	in vitro in HEK293 cells. Significance only as part of UGT1A6*2.	valproic acid
1448428115	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMID:27353638	CYP2C9	CYP2C9 *1/*2 + *1/*3 are associated with decreased dose of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C9 *1/*1.	yes	< 0.01	68	181	Unknown	Dosage	false		valproic acid
827643999	rs4244285	PMID:19638460	CYP2C19	Genotypes AA + AG are associated with increased dose of valproic acid in people with Myelodysplastic Syndromes as compared to genotype GG.	yes	= 0.0021	62		Unknown	Dosage,Metabolism/PK	false	when co-treated with azacitadine.	valproic acid
1183629441	rs2279020	PMID:24061200	GABRA1	Allele A is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.	no	= 0.8361	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
769146060	rs2606345	PMID:21121773	CYP1A1	Allele A is associated with increased risk of Seizures when treated with carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele C.	yes	= 0.00297	101		Central/South Asian	Efficacy,Metabolism/PK	false	This association was found in women but not in men.  The authors postulate that this is modulated through metabolism of estradiol.	carbamazepine; phenobarbital; phenytoin; valproic acid
827812675	rs2070959	PMID:21806385	UGT1A10; UGT1A6; UGT1A7; UGT1A8; UGT1A9	Genotype AG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype AA.	yes	< 1.0E-4	162		East Asian	Dosage,Metabolism/PK	false	Reported as UGT1A6 variant 541A>G.	valproic acid
1183612568	rs2298771	PMID:23859570	SCN1A	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.81	2073		Multiple groups	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs.	carbamazepine; valproic acid
981859218	rs2279020	PMCID:PMC3125053	GABRA1	Genotype GG is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to genotype AA.	yes	= 0.031	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1183629461	rs211037	PMID:24061200	GABRG2	Allele C is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele T.	no	= 0.718	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
769164996	rs1047891	PMID:20456087	CPS1	Genotypes AA + AC are associated with increased risk of Hyperammonemia when treated with antiepileptics and valproic acid in people with Epilepsy as compared to genotype CC.	not stated					Toxicity	false		antiepileptics; valproic acid
1183629456	rs2229944	PMID:24061200	GABRB2	Allele G is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele A.	no	= 0.1233	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1444608518	rs4880	PMCID:PMC4220988	SOD2	Genotypes AA + AG are associated with decreased likelihood of Drug Toxicity when exposed to valproic acid in people with Epilepsy as compared to genotype GG.	yes		169		East Asian	Toxicity	true	Drug toxicity here refers to hepatic toxicity as assayed by serum levels of the enzyme gamma-glutamyltransferase (gamma-GT) (IU/L). The authors used NONEM to assess the probability of elevation of gamma-GT in epileptic patients administered valproic acid (VPA) using a PK-PD model. The dose of VPA as well as the presence of intellectual disability were significant co-variates in the model, which predicted increased likelihood of of elevated gamma-GT levels in epileptics administered VPA.	valproic acid
1448821318	rs2298771	PMID:28753467	SCN1A	Allele C is associated with increased response to carbamazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, oxcarbazepine or valproic acid in children with Epilepsy as compared to allele T.	yes	= 0.013	216		European	Efficacy	true	All patients included in this study were receiving antiepileptic treatment as either mono or polytherapy.	carbamazepine; clobazam; ethosuximide; lamotrigine; levetiracetam; oxcarbazepine; valproic acid
981954215	rs2769605	PMCID:PMC3658129		Genotype CC is associated with decreased response to lithium or valproic acid in people with Bipolar Disorder as compared to genotypes CT + TT.	yes	= 0.013	284		East Asian	Efficacy	false		lithium; valproic acid
769164793	rs1105879	PMID:15761113	UGT1A10; UGT1A6; UGT1A7; UGT1A8; UGT1A9	Allele C is associated with increased glucuronidation of valproic acid.	yes					Metabolism/PK	false	in vitro in HEK293 cells. Significance only as part of UGT1A6*2.	valproic acid
1448265331	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	PMID:26223287	CYP2C19	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is not associated with increased risk of Weight gain when treated with valproic acid in men with Epilepsy as compared to CYP2C19 normal metabolizer genotype.	no	= 0.731	33	19	East Asian	Toxicity	false	Presence of a loss of function CYP2C19 allele was associated with greater risk of becoming overweight in females but not males. Patients took valproic acid for at least 6 months.	valproic acid
1448635002	rs1057910	PMID:23099353	CYP2C9	Genotype AA is not associated with metabolism of valproic acid in children with Epilepsy as compared to genotype AC.	not stated	= 0.41	94		East Asian	Metabolism/PK	true	VPA plasma concentrations and VPA plasma concentrations adjusted by weight did not differ between the three genotypes.The authors classified the A>C variant as *3.	valproic acid
981859232	rs2279020	PMCID:PMC3125053	GABRA1	Allele G is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele A.	yes	= 0.02	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
827812721	rs1019385	PMID:21806385	GRIN2B	Genotype AC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotype AA.	yes	< 1.0E-4	162		East Asian	Dosage,Metabolism/PK	false	Variant described as GRIN2B -200T>G (rsID not reported).	valproic acid
981954223	rs1565445	PMCID:PMC3658129	NTRK2	Genotype AA is not associated with response to lithium or valproic acid in people with Bipolar Disorder as compared to genotypes AG + GG.	no	= 0.458	284		East Asian	Efficacy	false		lithium; valproic acid
981859247	rs211037	PMCID:PMC3125053	GABRG2	Allele T is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.578	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1183701415	rs6883877	PMID:24236484	GABRA1	Genotype CT is not associated with increased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype CC.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction. However, when multiple variants were analyzed together a significant association was seen in logistic regression analysis of factors related to epilepsy treatment outcome; age, mesial temporal sclerosis vs unidentified, temporal lobe epilepsy, rs6883877, rs511310, and rs4828696 (p<0.0001).	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1448428159	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMID:27353638	CYP2C9	CYP2C9 *1/*2 + *1/*3 are not associated with concentrations of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C9 *1/*1.	no	= 0.16	68	181	Unknown	Metabolism/PK	false		valproic acid
827812732	rs6731242	PMID:21806385	UGT1A10; UGT1A7; UGT1A8; UGT1A9	Genotype GG is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes GG + GT.	no		162		East Asian	Dosage,Metabolism/PK	false	Variant described as UGT1A9 -1887T>G (rsID not reported).	valproic acid
1448634995	rs1057910	PMID:23099353	CYP2C9	Genotype AA is not associated with dose of valproic acid in children with Epilepsy as compared to genotype AC.	not stated	= 0.56	94		East Asian	Dosage	true	Dosage did not differ between the three genotypes. The authors classified the A>C variant as *3.	valproic acid
1183614112	rs17183814	PMID:23859570	SCN2A	Allele A is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele G.	no	= 0.81	1430		"Multiple groups, 701 patients from Malaysia (Malay, Chinese or Indian), 803 patients from Hong Kong (Han Chinese). "	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs after 1000 permutation testing for each marker or haplotype and Bonferroni correction.	carbamazepine; valproic acid
769164789	rs6759892	PMID:15761113	UGT1A10; UGT1A6; UGT1A7; UGT1A8; UGT1A9	Allele G is associated with increased glucuronidation of valproic acid.	yes					Dosage,Metabolism/PK	false	in vitro in HEK293 cells. Significance only as part of UGT1A6*2.	valproic acid
769164791	rs2070959	PMID:15761113	UGT1A10; UGT1A6; UGT1A7; UGT1A8; UGT1A9	Allele G is associated with increased glucuronidation of valproic acid.	yes					Dosage,Metabolism/PK	false	in vitro in HEK293 cells. Significance only as part of UGT1A6*2.	valproic acid
769164776	rs7439366	PMID:17687269	UGT2B7	Allele T is associated with increased response to lorazepam and valproic acid in healthy individuals as compared to allele C.	yes	< 0.05	14		East Asian	Efficacy	false	as part of the UGT2B7*2 haplotype. All healthy volunteers were also UGT2B15*2 homozygotes.	lorazepam; valproic acid
1183701437	rs511310	PMID:24236484		Genotype GG is not associated with decreased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype AA.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction. However, when multiple variants were analyzed together a significant association was seen in logistic regression analysis of factors related to epilepsy treatment outcome; age, mesial temporal sclerosis vs unidentified, temporal lobe epilepsy, rs6883877, rs511310, and rs4828696 (p<0.0001).	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1448634988	rs7439366	PMID:23099353	UGT2B7	Genotype CC is not associated with metabolism of valproic acid in children with Epilepsy.	not stated	= 0.9	94		East Asian	Metabolism/PK	true	VPA plasma concentrations and VPA plasma concentrations adjusted by weight did not differ between the three genotypes. The authors classified the C>T variant as *2.	valproic acid
1448265319	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	PMID:26223287	CYP2C19	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is associated with increased risk of Weight gain when treated with valproic acid in women with Epilepsy as compared to CYP2C19 normal metabolizer genotype.	yes	= 0.032	17	13	East Asian	Toxicity	false	Presence of a loss of function CYP2C19 allele was associated with greater risk of becoming overweight in females. Patients took valproic acid for at least 6 months.	valproic acid
769164769	rs7439366	PMID:17687269	UGT2B7	Allele T is associated with increased AUC of valproic acid in healthy individuals no disease as compared to allele C.	no					Dosage,Metabolism/PK	false	as part of the UGT2B7*2 haplotype. All healthy volunteers were also UGT2B15*2 homozygotes and were co-administered lorazepam.	valproic acid
769164770	rs7438284	PMID:17687269	UGT2B7	Allele A is associated with increased AUC of valproic acid in healthy individuals no disease as compared to allele T.	no					Metabolism/PK	false	as part of the UGT2B7*2 haplotype. All healthy volunteers were also UGT2B15*2 homozygotes and were co-administered lorazepam.	valproic acid
827812715	rs1019385	PMID:21806385	GRIN2B	Genotype CC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AC.	yes	< 1.0E-4	162		East Asian	Dosage,Metabolism/PK	false	and associated with significantly increased InCDR (serum concentration to dose ratio) compared to AA. Variant described as GRIN2B -200T>G (rsID not reported).	valproic acid
769164773	rs7438284	PMID:17687269	UGT2B7	Allele A is associated with increased response to lorazepam and valproic acid in healthy individuals as compared to allele T.	yes	< 0.05	14		East Asian	Efficacy	false	as part of the UGT2B7*2 haplotype. All healthy volunteers were also UGT2B15*2 homozygotes.	lorazepam; valproic acid
1448634981	rs7439366	PMID:23099353	UGT2B7	Genotype CC is not associated with dose of valproic acid in children with Epilepsy.	no	= 0.86	94		East Asian	Dosage	true	Dosage did not differ between the three genotypes. The authors classified the C>T variant as *2.	valproic acid
1445117542	rs2307441	PMCID:PMC3841971	POLG	Allele C is associated with increased risk of Toxic liver disease when treated with valproic acid as compared to allele T.	yes	= 5.1E-7	17	484	Unknown	Toxicity	false	17 individuals with suspected valproic acid-induced hepatotoxicity were identified; 8 had substitutions in the POLG gene. Two of these individuals carried the rs2307441 T>C change (3428 A>G or E1143G).  When combining this allele with the rs3087374 A allele, the frequency of the alleles was greater in those with valproic acid-induced hepatotoxicity as compared to in ethnically matched population controls. Please note alleles have been complemented to the plus chromosomal strand.	valproic acid
827812626	rs2070959	PMID:21806385	UGT1A10; UGT1A6; UGT1A7; UGT1A8; UGT1A9	Genotype GG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AG.	yes	< 1.0E-4	162		East Asian	Dosage,Metabolism/PK	false	and associated with significantly decreased InCDR (serum concentration to dose ratio) compared to AA. Reported as UGT1A6 variant 541A>G.	valproic acid
769146001	rs2032582	PMID:20417680	ABCB1	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.	no		228		Central/South Asian	Efficacy	false	"This is a three allele SNP.  No association was found between any of the three alleles (C,T,A) and response to antiepileptic drugs.
Subjects on the different medications were pooled."	carbamazepine; phenobarbital; phenytoin; valproic acid
1446902388	HLA-B*15:02:01	PMID:25647819	HLA-B	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine or valproic acid in people with Epilepsy.	no	= 0.256	6	30	East Asian	Toxicity	false	Controls were patients tolerant to lamotrigine or valproic acid after taking them for at least 3 months without developing a skin rash.	lamotrigine; valproic acid
1183701441	rs4828696	PMID:24236484	GABRA3	Genotype TT is not associated with increased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype CC.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction. However, when multiple variants were analyzed together a significant association was seen in logistic regression analysis of factors related to epilepsy treatment outcome; age, mesial temporal sclerosis vs unidentified, temporal lobe epilepsy, rs6883877, rs511310, and rs4828696 (p<0.0001).	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
769146005	rs1045642	PMID:20417680	ABCB1	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	no		282		Central/South Asian	Efficacy	false	Subjects on the different medications were pooled.	carbamazepine; phenobarbital; phenytoin; valproic acid
827700762	CYP2A6*1A; CYP2A6*4A	PMID:20089352	CYP2A6	CYP2A6 *4A is associated with decreased metabolism of valproic acid in people with Epilepsy as compared to CYP2A6 *1A/*1A.	yes	= 0.0055	179		East Asian	Metabolism/PK	false	As measured by the steady state plasma concentration of valproic acid (standardized for weight and dose).	valproic acid
1183701468	rs1112122	PMID:24236484	GABRA3	Genotype GG is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.	no	< 0.04	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1449001996	rs28898617	PMID:28763744	UGT1A10; UGT1A3; UGT1A4; UGT1A5; UGT1A6; UGT1A7; UGT1A8; UGT1A9	Allele G is associated with increased concentrations of valproic acid in children with Epilepsy as compared to allele A.	yes	= 0.0089	127		East Asian	Metabolism/PK	true	"Subjects were pediatric patients (2 to 18), diagnosed with epilepsy and regularly receiving sustained-release tablets of valproic acid 2x day at least 30 days.
Steady-state trough blood samples were collected 2 h prior to the next dose and plasma concentrations of VPA were divided by total daily dose and body weight to obtain concentration to dose ratio (CDRV) and log-transformed to obtain a normal distribution of values (lnCDRV).
The authors tested 48 SNPs and found only this one to be significant (without multiple testing corrections)."	valproic acid
827812612	rs6759892	PMID:21806385	UGT1A10; UGT1A6; UGT1A7; UGT1A8; UGT1A9	Genotype GG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes GT + TT.	yes	= 1.0E-4	162		East Asian	Dosage,Metabolism/PK	false	and associated with significantly decreased InCDR (serum concentration to dose ratio) compared to TT. Reported as UGT1A6 variant 19T>G.	valproic acid
1183701464	rs10068980	PMID:24236484	GABRA1	Genotype AA is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype GG.	no	< 0.02	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
769145998	rs1128503	PMID:20417680	ABCB1	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	no		228		Central/South Asian	Efficacy	false	Subjects on the different medications were pooled.	carbamazepine; phenobarbital; phenytoin; valproic acid
1183701460	rs6892782	PMID:24236484	GABRA1	Genotype CC is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1183701456	rs1157122	PMID:24236484	GABRA1	Genotype CC is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.	no	< 0.02	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1444936574	rs1800497	PMCID:PMC4540110	ANKK1	Genotypes AG + GG is associated with increased Weight gain when treated with valproic acid in people with Epilepsy as compared to genotype AA.	yes	= 0.0021	212		East Asian	Toxicity	false	Weight gain determined by change in body mass index (BMI) after 6 months of treatment. This association remained significant after Bonferroni correction, which was set at p < 0.0026. Please note alleles have been complemented to the plus chromosomal strand.	valproic acid
1449169153	rs12233719	PMID:29243113	UGT2B7	Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype GT.	no	< 0.00001	975		Multiple groups, Mostly Asian	Metabolism/PK	true	The GG genotype was associated with increased adj. serum concentration versus the GT genotype based on overall analysis (P < 0.00001). In subgroup of VPA monotherapy, adj. plasma VPA concentration was lower in TT genotype vs. GT (P < 0.00001) but was not significant in the combined therapy sub-group (P = 0.15).	valproic acid
1451126300	rs12608932	PMID:31624333	UNC13A	Allele C is not associated with response to valproic acid in people with Amyotrophic Lateral Sclerosis as compared to allele A.	no		151		Unknown	Efficacy	false		valproic acid
1183613417	rs17183814	PMID:23859570	SCN2A	Allele A is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele G.	no	= 0.64	1766		Multiple groups	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs.	carbamazepine; valproic acid
1444936566	rs1137101	PMCID:PMC4540110	LEPR	Genotypes AA + AG is associated with increased Weight gain when treated with valproic acid in people with Epilepsy as compared to genotype GG.	yes	< 0.001	212		East Asian	Toxicity	false	Weight gain determined by change in body mass index (BMI) after 6 months of treatment. This association remained significant after Bonferroni correction, which was set at p < 0.0026.	valproic acid
981954797	rs1128503	PMID:18812236	ABCB1	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1451126286	rs616147	PMID:31624333	MOBP	Allele A is not associated with response to valproic acid in people with Amyotrophic Lateral Sclerosis as compared to allele G.	no		148		Unknown	Efficacy	false		valproic acid
981954805	rs2032582	PMID:18812236	ABCB1	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
827812640	rs1105879	PMID:21806385	UGT1A6	Genotype CC is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AC.	yes	< 1.0E-4	162		East Asian	Dosage,Metabolism/PK	false	and associated with significantly decreased InCDR (serum concentration to dose ratio) compared to AA. Reported as UGT1A6 variant 552A>C.	valproic acid
827812655	rs6759892	PMID:21806385	UGT1A10; UGT1A6; UGT1A7; UGT1A8; UGT1A9	Genotype GT is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype TT.	yes	< 1.0E-4	162		East Asian	Dosage,Metabolism/PK	false	Reported as UGT1A6 variant 19T>G.	valproic acid
1445117531	rs3087374	PMCID:PMC3841971	POLG	Allele A is associated with increased risk of Toxic liver disease when treated with valproic acid as compared to allele C.	yes	= 5.1E-7	17	484	Unknown	Toxicity	false	17 individuals with suspected valproic acid-induced hepatotoxicity were identified; 8 had substitutions in the POLG gene. Five of these individuals carried the rs3087374 C>A change (3708 G>T or Q1236H). When compared against ethnically matched population controls, the frequency of the A allele is significantly greater in patients with valproic acid-induced hepatotoxicity. Additionally, when combining this allele and the rs2307441 C allele, the p-value was even more significant. Please note alleles have been complemented to the plus chromosomal strand.	valproic acid
1449169125	rs7668258	PMID:29243113	UGT2B7	Genotype TT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.	yes	= 0.002	123		Multiple groups, Mostly Asian	Metabolism/PK	true	4 studies evaluated the association between CC & TT and adj. serum concentration of VPA. In overall analysis of 4 studies found no association with genotype and adj. serum concentration (P = 0.35). In subgroup analysis, the TT genotype was not significantly associated with serum concentration versus CC genotype in monotherapy (P =0.71) but was associated with increased concentrations based on combination therapy data (P = 0.002). No sub-group anayses were done by age.	valproic acid
981954817	rs2032582	PMID:18812236	ABCB1	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1444936599	rs10789038	PMCID:PMC4540110	PRKAA2	Genotypes AG + GG is associated with increased Weight gain when treated with valproic acid in people with Epilepsy as compared to genotype AA.	no	= 0.04	212		East Asian	Toxicity	false	Weight gain determined by change in body mass index (BMI) over 6 months of treatment. This association did not remain significant after Bonferroni correction, which was set at p < 0.0026.	valproic acid
981954829	rs1045642	PMID:18812236	ABCB1	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1449169135	rs7668258	PMID:29243113	UGT2B7	Genotype CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.	yes	= 0.004	219		Multiple groups, Mostly Asian	Metabolism/PK	true	In overall analysis CT genotype was associated with increased serum concentration of valproic acid as compared with the CC genotype (P = 0.01) as well as in the sub-group analysis in combination therapy (P = 0.04). Hoqever, the CT genotype also did not significantly affect the adjusted serum concentration as compared with CC genotype based on monotherapy data (P = 0.10).	valproic acid
981954839	rs2032582	PMID:18812236	ABCB1	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1448613065	rs2740574	PMID:28343093	CYP3A4	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1448613071	rs2687116	PMID:28343093	CYP3A4	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele A.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1449169145	rs12233719	PMID:29243113	UGT2B7	Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT.	yes	= 0.0006	586		Multiple groups, Mostly Asian	Metabolism/PK	true	Five studies evaluated the association between genotypes and adjusted serum concentration of overall analysis (P = 0.01). In the monotherapy subgroup, adjusted plasma VPA concentration was significantly lower in the TT genotype (P = 0.0006) but not in combination therapy subgroup (P = 0.58).	valproic acid
1448613059	rs3892097	PMID:28343093	CYP2D6	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1449169100	rs7439366	PMID:29243113	UGT2B7	Genotype TT is associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.	yes	= 0.02	103		Multiple groups, Asian	Metabolism/PK	true	In two sub-group analyses the TT genotype was associated with dose adj. concentrations of valproic acid (VPA) but in opposite association with VPA concentration: 1) one study in combination therapy TT was associated with increased concentration vs. CC and 2) in two studies in a sub-group analysis of children on monotherapy the TT genotype was associated with decreased concentrations vs. the CC genotype. When evaluated overall there was no association.	valproic acid
1444608439	GSTM1 non-null; GSTM1 null	PMCID:PMC4220988	GSTM1	GSTM1 null is not associated with likelihood of Drug Toxicity when exposed to valproic acid in people with as compared to GSTM1 non-null.	no		237		East Asian	Toxicity	true	Drug toxicity here refers to hepatic toxicity as assayed by serum levels of the enzyme gamma-glutamyltransferase (gamma-GT)  (IU/L). The authors used NONEM to assess the probability of elevation of gamma-GT in epileptic patients administered valproic acid (VPA).	valproic acid
1447945718	rs1800012	PMID:26727275	COL1A1	Genotypes AA + AC is associated with decreased bone density when treated with valproic acid in people with Epilepsy as compared to genotype CC.	yes	< 0.05	18		Unknown	Toxicity	false	Bone density in left femoral neck  and lumbar spine was lower in variant carriers vs homozygous non-carrier.	valproic acid
1448519661	rs1731017	PMID:27918244	ABAT	Genotypes AA + AG is associated with increased resistance to valproic acid in people with Epilepsy as compared to genotype GG.	no	= 0.120	70	131	East Asian	Efficacy	false	This was not significant after Bonferroni correction.	valproic acid
1449169116	rs7439366	PMID:29243113	UGT2B7	Genotype CT is not associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.	no	= 0.09	913		Multiple groups, Mostly Asian	Metabolism/PK	true	The CT genotype was not associated with dose adj. concentrations of valproic acid (VPA) overall in 10 studies (P = 0.24). Sub-group analyses included monotherapy and combination therapy, nor by age.	valproic acid
1450968771	HLA-A*02:01	PMCID:PMC6989248	HLA-A	HLA-A *02:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine or valproic acid in people with Drug Hypersensitivity, severe cutaneous adverse reactions and Epilepsy.	no		5		Unknown	Toxicity	false	"This allele was present in 3 of 5 cases alongside other HLA alleles. Case 1: HLA-A*02:01/*26:01, HLA-B*15:11/*51:01, HLA-C*03:04/*15:02; Case 3 : HLA-A*02:01/*02:01, HLA-B*35:01/*51:01, HLA-C*03:04/*14:02; Case 4 : HLA-A*02:01/*02:10, HLA-B*15:11/*40:06, HLA-C*03:04/*08:01. Authors state ""Korean allele frequencies of the five cases' common alleles were 17.62% for -A*02:01""."	carbamazepine; valproic acid
827812759	rs7668258	PMID:21806385	UGT2B7	Genotype TT is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CC + CT.	no		162		East Asian	Dosage,Metabolism/PK	false	Variant described as UGT2B7 -161C>T (rsID not reported, from the UGT nomenclature website).	valproic acid
1448635034	UGT1A6*1a; UGT1A6*2a; UGT1A6*3a; UGT1A6*4a; UGT1A6*8	PMID:23099353	UGT1A6	UGT1A6 *1a is associated with metabolism of valproic acid in children with Epilepsy as compared to UGT1A6 *2a + *3a + *4a + *8.	yes	= 0.027	94		East Asian	Metabolism/PK	true	The authors only genotyped three SNPs in the UGT1A6 gene: rs6759892 T>G rs2070959 A>G rs1105879 A>C The * alleles were classified as follows: *1 (TAA), *2 (GGC), *3 (GAA), *4 (GAC), *8 (TGC), *10 (GGA). The authors only provided the * and number but not letter. Here *1 corresponds to *1a, *2 corresponds to *2a, etc. The *10 that the authors provide corresponds most closely to *3b here. *1/*1 are wild-type, *1/*2, *1/*3, *1/*4, *1/*8 are single heterozygous, and *2/*2, *2/*4, or *2/*10 are double heterozygous. The authors evaluated differences in VPA dose, VPA concentration in plasma, and adjusted VPA concentration (concentration adjusted by weight) . No significant differences were found when comparing VPA plasma concentration between genotypes. Significant differences were found in adjusted VPA concentration when comparing between genotypes. Reported p-values are for those comparisons. After the initial comparisons were made for all patients, the same genotypes were compared in a subset of patients (n=34) ages 0-4. No corrections were done for multiple hypothesis testing.	valproic acid
1444608478	CYP2C9*1; CYP2C9*3	PMCID:PMC4220988	CYP2C9	CYP2C9 *3 is not associated with clearance of valproic acid in people with Epilepsy as compared to CYP2C9 *1.	no		237		East Asian	Metabolism/PK	true	Clearance here refers to apparent oral clearance as assayed by serum concentration of valproic acid (VPA) (micrograms/ml). The authors used NONEM to assess serum concentration of VPA.	valproic acid
827691666	rs1057910	PMID:14597963	CYP2C9	Allele C is associated with decreased enzyme activity of CYP2C9 when assayed with valproic acid in human liver microsomes.	not stated					Metabolism/PK	false	due to increased Km. Formation rates of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA were all reduced. This was also seen with expressed recombinant protein.	valproic acid
981859149	rs1045642	PMCID:PMC3125053	ABCB1	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	no	= 0.39	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1444608466	GSTT1 non-null; GSTT1 null	PMCID:PMC4220988	GSTT1	GSTT1 null is not associated with likelihood of Drug Toxicity when exposed to valproic acid in people with as compared to GSTT1 non-null.	no		237		East Asian	Toxicity	true	Drug toxicity here refers to hepatic toxicity as assayed by serum levels of the enzyme gamma-glutamyltransferase (gamma-GT)  (IU/L). The authors used NONEM to assess the probability of elevation of gamma-GT in epileptic patients administered valproic acid (VPA).	valproic acid
827691673	rs1799853	PMID:14597963	CYP2C9	Allele T is associated with decreased enzyme activity of CYP2C9 when assayed with valproic acid in human liver microsomes.	not stated					Metabolism/PK	false	due to reduced Vmax. Formation rates of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA were all reduced. This was also seen with expressed recombinant protein.	valproic acid
1448428186	CYP2C19*1; CYP2C19*2	PMID:27353638	CYP2C19	CYP2C19 *1/*2 + *2/*2 are not associated with concentrations of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C19 *1/*1.	no	= 0.15	68	181	Unknown	Dosage	false	Dose-adjusted serum concentration and absolute serum concentration were not significant.	valproic acid
981751120	rs17183814	PMCID:PMC2767285	SCN2A	Allele A is associated with resistance to carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.	yes	= 0.06	336	160	Central/South Asian	Efficacy	false	p value was above significance level after correction for multiple testing.  Authors note that association was found at the allele level but not at the genotype level, and that this may be due to a low number of AA individuals.	carbamazepine; phenobarbital; phenytoin; valproic acid
827691648	rs1057910	PMID:20089352	CYP2C9	Genotype AC is associated with increased mean plasma drug concentrations of valproic acid in people with Epilepsy as compared to genotype AA.	yes	= 1.0E-4	179		East Asian	Metabolism/PK,Other	false	No CYP2C9*3 homozygotes were seen. Significance reported for one *3 allele vs no *3 alleles.	valproic acid
1448428173	CYP2C19*1; CYP2C19*2	PMID:27353638	CYP2C19	CYP2C19 *1/*2 + *2/*2 are not associated with dose of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C19 *1/*1.	no	= 0.57	68	181	Unknown	Dosage	false		valproic acid
1448635009	UGT1A6*1a; UGT1A6*2a; UGT1A6*3a; UGT1A6*4a; UGT1A6*8	PMID:23099353	UGT1A6	UGT1A6 *1a is associated with decreased dose of valproic acid in children with Epilepsy as compared to UGT1A6 *2a + *3a + *4a + *8.	yes	= 0.003	94		East Asian	Dosage	true	The authors only genotyped three SNPs in the UGT1A6 gene: rs6759892 T>G rs2070959 A>G rs1105879 A>C The * alleles were classified as follows: *1 (TAA), *2 (GGC), *3 (GAA), *4 (GAC), *8 (TGC), *10 (GGA). The authors only provided the * and number but not letter. Here *1 corresponds to *1a, *2 corresponds to *2a, etc. The *10 that the authors provide corresponds most closely to *3b here. *1/*1 are wild-type, *1/*2, *1/*3, *1/*4, *1/*8 are single heterozygous, and *2/*2, *2/*4, or *2/*10 are double heterozygous. The authors evaluated differences in VPA dose, VPA concentration in plasma, and weight adjusted VPA concentration in plasma. Reported p-values are for those comparisons. After the initial comparisons were made for all patients, the same genotypes were compared in a subset of patients (n=34) ages 0-4. No corrections were done for multiple hypothesis testing.	valproic acid
827812746	rs2741049	PMID:21806385	UGT1A10; UGT1A7; UGT1A8; UGT1A9	Genotype CC is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CT + TT.	no		162		East Asian	Dosage,Metabolism/PK	false	Variant described as UGT1A9 i399T>C (rsID not reported, UGT nomenclature website used).	valproic acid
1183680877	HLA-B*15:02:01	PMID:23692434	HLA-B	HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with valproic acid in people with Epilepsy.	no	= 1.0	3	15	East Asian	Toxicity	false	Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele did NOT have a significantly greater risk of developing SJS/TEN, compared to those without the allele. This study was done in a case-control format, where 3 cases were compared against 15 controls; cases developed SJS/TEN on valproic acid, controls did not.  p < 0.01 was considered significant, after adjustment for multiple comparisons using Bonferroni's correction.	valproic acid
827696054	rs1057910	PMID:20602621	CYP2C9	Allele C is not associated with plasma concentration of the 4-ene-VPA metabolite of valproic acid in people with Epilepsy as compared to allele A.	no		68	50	Near Eastern	Metabolism/PK,Toxicity	false		valproic acid
1448261553	rs7668258	PMID:27406852	UGT2B7	Genotypes CC + CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT.	yes	= 0.022	149		East Asian	Metabolism/PK	true	as measured by dose adjusted plasma VPA.	valproic acid
1448613053	rs9332120	PMID:28343093	CYP2C9	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
981859171	rs1128503	PMCID:PMC3125053	ABCB1	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	no	= 0.71	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1183606890	rs3812718	PMID:23859570	SCN1A	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.39	2475		Multiple groups	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs.	carbamazepine; valproic acid
1448428210	CYP2C19*1; CYP2C19*17	PMID:27353638	CYP2C19	CYP2C19 *17/*17 is not associated with concentrations of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C19 *1/*1.	no	= 0.52	8	95	Unknown	Dosage	false	Neither dose-adjusted serum concentrations nor absolute serum concentrations were significant.	valproic acid
1450968980	HLA-C*03:04:01:01	PMCID:PMC6989248	HLA-C	HLA-C *03:04:01:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine or valproic acid in people with Drug Hypersensitivity, severe cutaneous adverse reactions and Epilepsy.	no		5		Unknown	Toxicity	false	"This allele was present in 3 of 5 cases alongside other HLA alleles. Case 1: HLA-A*02:01/*26:01, HLA-B*15:11/*51:01, HLA-C*03:04/*15:02; Case 3 : HLA-A*02:01/*02:01, HLA-B*35:01/*51:01, HLA-C*03:04/*14:02; Case 4 : HLA-A*02:01/*02:10, HLA-B*15:11/*40:06, HLA-C*03:04/*08:01. Authors state ""Korean allele frequencies of the five cases' common alleles were 8.97% for -C*03:04""."	carbamazepine; valproic acid
1183611749	rs3812718	PMID:23859570	SCN1A	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.39	1470		"Multiple groups, 701 patients from Malaysia (Malay, Chinese or Indian), 803 patients from Hong Kong (Han Chinese). "	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs after 1000 permutation testing for each marker or haplotype and Bonferroni correction.	carbamazepine; valproic acid
1444608497	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC4220988	CYP2C19	CYP2C19 *2 + *3 are not associated with clearance of valproic acid in people with Epilepsy as compared to CYP2C19 *1.	no		237		East Asian	Metabolism/PK	true	Clearance here refers to apparent oral clearance as assayed by serum concentration of valproic acid (VPA) (micrograms/ml). The authors used NONEM to assess serum concentration of VPA.	valproic acid
1183612769	rs2298771	PMID:23859570	SCN1A	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.81	1448		"Multiple groups, 701 patients from Malaysia (Malay, Chinese or Indian), 803 patients from Hong Kong (Han Chinese). "	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs after 1000 permutation testing for each marker or haplotype and Bonferroni correction. Variant described as Thr1067Ala A>G therefore minor allele taken as G (here alleles are complemented for the plus chromosomal strand T>C).	carbamazepine; valproic acid
981859179	rs2032582	PMCID:PMC3125053	ABCB1	Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.	yes	= 0.03	402		Central/South Asian	Efficacy	false	"However, The study reports that the genotype frequencies of 2677G>T ABCB1 polymorphism did not differ significantly in the drug-resistant versus the
drug-responsive epilepsy patients for GT genotype (P =0.71, OR = 1.14, 95% CI = 0.55 - 2.36), for TT genotype (P = 0.87, OR = 1.06, 95% CI = 0.49 - 2.26) and for AT genotype (P = 0.39, OR = 0.53, 95% CI = 0.13 - 2.24). (The alleles are given on the negative strand in the article.)"	carbamazepine; phenytoin; valproic acid
1448613046	rs1065852	PMID:28343093	CYP2D6	Allele A is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele G.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
827812774	rs7439366	PMID:21806385	UGT2B7	Genotype CC is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CT + TT.	no		162		East Asian	Dosage,Metabolism/PK	false	Variant reported as UGT2B7 802T>C (rsID not reported, obtained from the UGT nomenclature website).	valproic acid
1448261536	rs3816877	PMID:27406852	APEH	Genotype CC is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CT.	yes	"= 	0.006"	149		East Asian	Metabolism/PK	true	as measured by dose adjusted plasma VPA. Note: the mean age differed between CC and CT patient groups but was not significant (0.066) No TT homozygotes were observed.	valproic acid
1448428199	CYP2C19*1; CYP2C19*17	PMID:27353638	CYP2C19	CYP2C19 *17/*17 is not associated with dose of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C19 *1/*1.	no	= 0.87	8	95	Unknown	Dosage	false		valproic acid
827812768	rs28365062	PMID:21806385	UGT2B7	Genotype GG is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AG.	no		162		East Asian	Dosage,Metabolism/PK	false	Variant described as UGT2B7 735A>G (rsID not reported, UGT nomenclature website used).	valproic acid
827696045	rs1799853	PMID:20602621	CYP2C9	Allele T is not associated with plasma concentration of the 4-ene-VPA metabolite of valproic acid in people with Epilepsy as compared to allele C.	no		68	50	Near Eastern	Metabolism/PK,Toxicity	false		valproic acid
827812782	rs1799883	PMID:21806385	FABP2	Genotype TT is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CC + CT.	no		162		East Asian	Dosage,Metabolism/PK	false	Variant reported as FABP2 163G>A (rsID not reported).	valproic acid
769164580	rs2269577	PMID:19564049	XBP1	Allele G is associated with increased likelihood of prophylactic treatment response when treated with valproic acid in people with Bipolar Disorder as compared to allele C.	yes	= 0.002	23	28	East Asian	Efficacy	false	[[stat_test:  chi square]	valproic acid
981859192	rs17183814	PMCID:PMC3125053	SCN2A	Allele A is associated with non-response when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	yes	= 0.03	402		Central/South Asian	Efficacy	false	Authors note that association was found at the allele level but not at the genotype level, and that this may be due to a low number of AA individuals.	carbamazepine; phenytoin; valproic acid